306 related articles for article (PubMed ID: 30373366)
1. Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome.
Xie SC; Gillett DL; Spillman NJ; Tsu C; Luth MR; Ottilie S; Duffy S; Gould AE; Hales P; Seager BA; Charron CL; Bruzzese F; Yang X; Zhao X; Huang SC; Hutton CA; Burrows JN; Winzeler EA; Avery VM; Dick LR; Tilley L
J Med Chem; 2018 Nov; 61(22):10053-10066. PubMed ID: 30373366
[TBL] [Abstract][Full Text] [Related]
2. Structure- and function-based design of Plasmodium-selective proteasome inhibitors.
Li H; O'Donoghue AJ; van der Linden WA; Xie SC; Yoo E; Foe IT; Tilley L; Craik CS; da Fonseca PC; Bogyo M
Nature; 2016 Feb; 530(7589):233-6. PubMed ID: 26863983
[TBL] [Abstract][Full Text] [Related]
3. Design of proteasome inhibitors with oral efficacy in vivo against
Xie SC; Metcalfe RD; Mizutani H; Puhalovich T; Hanssen E; Morton CJ; Du Y; Dogovski C; Huang SC; Ciavarri J; Hales P; Griffin RJ; Cohen LH; Chuang BC; Wittlin S; Deni I; Yeo T; Ward KE; Barry DC; Liu B; Gillett DL; Crespo-Fernandez BF; Ottilie S; Mittal N; Churchyard A; Ferguson D; Aguiar ACC; Guido RVC; Baum J; Hanson KK; Winzeler EA; Gamo FJ; Fidock DA; Baud D; Parker MW; Brand S; Dick LR; Griffin MDW; Gould AE; Tilley L
Proc Natl Acad Sci U S A; 2021 Sep; 118(39):. PubMed ID: 34548400
[TBL] [Abstract][Full Text] [Related]
4. Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents.
Stokes BH; Yoo E; Murithi JM; Luth MR; Afanasyev P; da Fonseca PCA; Winzeler EA; Ng CL; Bogyo M; Fidock DA
PLoS Pathog; 2019 Jun; 15(6):e1007722. PubMed ID: 31170268
[TBL] [Abstract][Full Text] [Related]
5. The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria.
Li H; Bogyo M; da Fonseca PC
FEBS J; 2016 Dec; 283(23):4238-4243. PubMed ID: 27286897
[TBL] [Abstract][Full Text] [Related]
6. Support vector machine based prediction of P. falciparum proteasome inhibitors and development of focused library by molecular docking.
Subramaniam S; Mehrotra M; Gupta D
Comb Chem High Throughput Screen; 2011 Dec; 14(10):898-907. PubMed ID: 21843142
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and docking studies of novel dipeptidyl boronic acid proteasome inhibitors constructed from αα- and αβ-amino acids.
Shi J; Lei M; Wu W; Feng H; Wang J; Chen S; Zhu Y; Hu S; Liu Z; Jiang C
Bioorg Med Chem Lett; 2016 Apr; 26(8):1958-62. PubMed ID: 26965867
[TBL] [Abstract][Full Text] [Related]
8. Antimalarial proteasome inhibitor reveals collateral sensitivity from intersubunit interactions and fitness cost of resistance.
Kirkman LA; Zhan W; Visone J; Dziedziech A; Singh PK; Fan H; Tong X; Bruzual I; Hara R; Kawasaki M; Imaeda T; Okamoto R; Sato K; Michino M; Alvaro EF; Guiang LF; Sanz L; Mota DJ; Govindasamy K; Wang R; Ling Y; Tumwebaze PK; Sukenick G; Shi L; Vendome J; Bhanot P; Rosenthal PJ; Aso K; Foley MA; Cooper RA; Kafsack B; Doggett JS; Nathan CF; Lin G
Proc Natl Acad Sci U S A; 2018 Jul; 115(29):E6863-E6870. PubMed ID: 29967165
[TBL] [Abstract][Full Text] [Related]
9. Novel aromatic sulfonyl naphthalene-based boronates as 20S proteasome inhibitors.
Liu H; Wu J; Ge Y; Li A; Li J; Liu Z; Xu Y; Xu Q; Li Y
Bioorg Med Chem; 2018 Mar; 26(5):1050-1061. PubMed ID: 29426629
[TBL] [Abstract][Full Text] [Related]
10. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design.
Schrader J; Henneberg F; Mata RA; Tittmann K; Schneider TR; Stark H; Bourenkov G; Chari A
Science; 2016 Aug; 353(6299):594-8. PubMed ID: 27493187
[TBL] [Abstract][Full Text] [Related]
11. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
[TBL] [Abstract][Full Text] [Related]
12. Development of a Highly Selective Plasmodium falciparum Proteasome Inhibitor with Anti-malaria Activity in Humanized Mice.
Zhan W; Zhang H; Ginn J; Leung A; Liu YJ; Michino M; Toita A; Okamoto R; Wong TT; Imaeda T; Hara R; Yukawa T; Chelebieva S; Tumwebaze PK; Lafuente-Monasterio MJ; Martinez-Martinez MS; Vendome J; Beuming T; Sato K; Aso K; Rosenthal PJ; Cooper RA; Meinke PT; Nathan CF; Kirkman LA; Lin G
Angew Chem Int Ed Engl; 2021 Apr; 60(17):9279-9283. PubMed ID: 33433953
[TBL] [Abstract][Full Text] [Related]
13. Identification of potent and selective non-covalent inhibitors of the Plasmodium falciparum proteasome.
Li H; Tsu C; Blackburn C; Li G; Hales P; Dick L; Bogyo M
J Am Chem Soc; 2014 Oct; 136(39):13562-5. PubMed ID: 25226494
[TBL] [Abstract][Full Text] [Related]
14. Structures revealing mechanisms of resistance and collateral sensitivity of Plasmodium falciparum to proteasome inhibitors.
Hsu HC; Li D; Zhan W; Ye J; Liu YJ; Leung A; Qin J; Crespo B; Gamo FJ; Zhang H; Cui L; Roth A; Kirkman LA; Li H; Lin G
Nat Commun; 2023 Dec; 14(1):8302. PubMed ID: 38097652
[TBL] [Abstract][Full Text] [Related]
15. Defining the Determinants of Specificity of Plasmodium Proteasome Inhibitors.
Yoo E; Stokes BH; de Jong H; Vanaerschot M; Kumar T; Lawrence N; Njoroge M; Garcia A; Van der Westhuyzen R; Momper JD; Ng CL; Fidock DA; Bogyo M
J Am Chem Soc; 2018 Sep; 140(36):11424-11437. PubMed ID: 30107725
[TBL] [Abstract][Full Text] [Related]
16. 3D-QSAR-aided design, synthesis, in vitro and in vivo evaluation of dipeptidyl boronic acid proteasome inhibitors and mechanism studies.
Lei M; Feng H; Wang C; Li H; Shi J; Wang J; Liu Z; Chen S; Hu S; Zhu Y
Bioorg Med Chem; 2016 Jun; 24(11):2576-2588. PubMed ID: 27117691
[TBL] [Abstract][Full Text] [Related]
17. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
[TBL] [Abstract][Full Text] [Related]
18. Mitigating the risk of antimalarial resistance via covalent dual-subunit inhibition of the Plasmodium proteasome.
Deni I; Stokes BH; Ward KE; Fairhurst KJ; Pasaje CFA; Yeo T; Akbar S; Park H; Muir R; Bick DS; Zhan W; Zhang H; Liu YJ; Ng CL; Kirkman LA; Almaliti J; Gould AE; Duffey M; O'Donoghue AJ; Uhlemann AC; Niles JC; da Fonseca PCA; Gerwick WH; Lin G; Bogyo M; Fidock DA
Cell Chem Biol; 2023 May; 30(5):470-485.e6. PubMed ID: 36963402
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and biological evaluation of novel non-peptide boronic acid derivatives as proteasome inhibitors.
Ge Y; Li A; Wu J; Feng H; Wang L; Liu H; Xu Y; Xu Q; Zhao L; Li Y
Eur J Med Chem; 2017 Mar; 128():180-191. PubMed ID: 28182990
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of curcumin derivatives modified with α-amino boronic acid as proteasome inhibitors.
Zhang W; Bai H; Han L; Zhang H; Xu B; Cui J; Wang X; Ge Z; Li R
Bioorg Med Chem Lett; 2018 Aug; 28(14):2459-2464. PubMed ID: 29886021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]